TrialThe American journal of drug and alcohol abuse2023

Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.

Jermaine D Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.